Selected research
Industry Growth & Trends
Global Radiopharmaceutical CDMO Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Radiopharmaceutical CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Radiopharmaceutical CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Radiopharmaceutical CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Radiopharmaceutical CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Radiopharmaceutical CDMO market include Almac, AtomVie, Cardinal Health, Cyclotek, Eckert & Ziegler, Seibersdorf Labor GmbH, Evergreen Theragnostics, Lantheus and Medi-Radiopharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Radiopharmaceutical CDMO market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Radiopharmaceutical CDMO market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Radiopharmaceutical CDMO market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Radiopharmaceutical CDMO.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Radiopharmaceutical CDMO market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Radiopharmaceutical CDMO Market by Company
Almac
AtomVie
Cardinal Health
Cyclotek
Eckert & Ziegler
Seibersdorf Labor GmbH
Evergreen Theragnostics
Lantheus
Medi-Radiopharma
Minerva Imaging
NorthStar
ROTOP Pharmaka GmbH
Nucleus RadioPharma
PharmaLogic
Radiopharmaceutical CDMO Segment by Type
R&D CDMO
Production CDMO
Radiopharmaceutical CDMO Segment by Application
Diagnosis
Treatment
Radiopharmaceutical CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceutical CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceutical CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceutical CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Radiopharmaceutical CDMO companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- R&D CDMO
- Production CDMO
Applications
- Diagnosis
- Treatment
Companies covered
- Almac
- AtomVie
- Cardinal Health
- Cyclotek
- Eckert & Ziegler
- Seibersdorf Labor GmbH
- Evergreen Theragnostics
- Lantheus
- Medi-Radiopharma
- Minerva Imaging
- NorthStar
- ROTOP Pharmaka GmbH
- Nucleus RadioPharma
- PharmaLogic
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Radiopharmaceutical CDMO Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Radiopharmaceutical CDMO Market Size by Region (2021-2032)
- 1.4.1 Global Radiopharmaceutical CDMO Market Size by Region (2021-2026)
- 1.4.2 Global Radiopharmaceutical CDMO Market Size by Region (2027-2032)
- 1.5 Key Regions Radiopharmaceutical CDMO Market Size (2021-2032)
- 1.5.1 North America Radiopharmaceutical CDMO Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Radiopharmaceutical CDMO Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Radiopharmaceutical CDMO Market Size Growth Rate (2021-2032)
- 1.5.4 South America Radiopharmaceutical CDMO Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Radiopharmaceutical CDMO Market Size Growth Rate (2021-2032)
2 Radiopharmaceutical CDMO Market by Type
- 2.1 Type Introduction
- 2.1.1 R&D CDMO
- 2.1.2 Production CDMO
- 2.2 Global Radiopharmaceutical CDMO Market Size by Type
- 2.2.1 Global Radiopharmaceutical CDMO Market Size Overview by Type (2021-2032)
- 2.2.2 Global Radiopharmaceutical CDMO Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Radiopharmaceutical CDMO Market Size Forecasted by Type (2027-2032)
- 2.3 Global Radiopharmaceutical CDMO Market Size by Regions
- 2.3.1 North America Radiopharmaceutical CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Radiopharmaceutical CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Radiopharmaceutical CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Radiopharmaceutical CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Radiopharmaceutical CDMO Market Size Breakdown by Type (2021-2026)
3 Radiopharmaceutical CDMO Market by Application
- 3.1 Type Introduction
- 3.1.1 Diagnosis
- 3.1.2 Treatment
- 3.2 Global Radiopharmaceutical CDMO Market Size by Application
- 3.2.1 Global Radiopharmaceutical CDMO Market Size Overview by Application (2021-2032)
- 3.2.2 Global Radiopharmaceutical CDMO Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Radiopharmaceutical CDMO Market Size Forecasted by Application (2027-2032)
- 3.3 Global Radiopharmaceutical CDMO Market Size by Regions
- 3.3.1 North America Radiopharmaceutical CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Radiopharmaceutical CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Radiopharmaceutical CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Radiopharmaceutical CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Radiopharmaceutical CDMO Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Radiopharmaceutical CDMO Industry Trends
- 4.2 Radiopharmaceutical CDMO Industry Drivers
- 4.3 Radiopharmaceutical CDMO Industry Opportunities and Challenges
- 4.4 Radiopharmaceutical CDMO Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Radiopharmaceutical CDMO Revenue (2021-2026)
- 5.2 Global Radiopharmaceutical CDMO Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Radiopharmaceutical CDMO Key Company Headquarters & Area Served
- 5.4 Global Radiopharmaceutical CDMO Company, Product Type & Application
- 5.5 Global Radiopharmaceutical CDMO Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Radiopharmaceutical CDMO Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Radiopharmaceutical CDMO Players Market Share by Revenue in 2025
- 5.6.3 2025 Radiopharmaceutical CDMO Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Almac
- 6.1.1 Almac Company Information
- 6.1.2 Almac Business Overview
- 6.1.3 Almac Radiopharmaceutical CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Almac Radiopharmaceutical CDMO Product Portfolio
- 6.1.5 Almac Recent Developments
- 6.2 AtomVie
- 6.2.1 AtomVie Company Information
- 6.2.2 AtomVie Business Overview
- 6.2.3 AtomVie Radiopharmaceutical CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 AtomVie Radiopharmaceutical CDMO Product Portfolio
- 6.2.5 AtomVie Recent Developments
- 6.3 Cardinal Health
- 6.3.1 Cardinal Health Company Information
- 6.3.2 Cardinal Health Business Overview
- 6.3.3 Cardinal Health Radiopharmaceutical CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Cardinal Health Radiopharmaceutical CDMO Product Portfolio
- 6.3.5 Cardinal Health Recent Developments
- 6.4 Cyclotek
- 6.4.1 Cyclotek Company Information
- 6.4.2 Cyclotek Business Overview
- 6.4.3 Cyclotek Radiopharmaceutical CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Cyclotek Radiopharmaceutical CDMO Product Portfolio
- 6.4.5 Cyclotek Recent Developments
- 6.5 Eckert & Ziegler
- 6.5.1 Eckert & Ziegler Company Information
- 6.5.2 Eckert & Ziegler Business Overview
- 6.5.3 Eckert & Ziegler Radiopharmaceutical CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Eckert & Ziegler Radiopharmaceutical CDMO Product Portfolio
- 6.5.5 Eckert & Ziegler Recent Developments
- 6.6 Seibersdorf Labor GmbH
- 6.6.1 Seibersdorf Labor GmbH Company Information
- 6.6.2 Seibersdorf Labor GmbH Business Overview
- 6.6.3 Seibersdorf Labor GmbH Radiopharmaceutical CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Seibersdorf Labor GmbH Radiopharmaceutical CDMO Product Portfolio
- 6.6.5 Seibersdorf Labor GmbH Recent Developments
- 6.7 Evergreen Theragnostics
- 6.7.1 Evergreen Theragnostics Company Information
- 6.7.2 Evergreen Theragnostics Business Overview
- 6.7.3 Evergreen Theragnostics Radiopharmaceutical CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 Evergreen Theragnostics Radiopharmaceutical CDMO Product Portfolio
- 6.7.5 Evergreen Theragnostics Recent Developments
- 6.8 Lantheus
- 6.8.1 Lantheus Company Information
- 6.8.2 Lantheus Business Overview
- 6.8.3 Lantheus Radiopharmaceutical CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Lantheus Radiopharmaceutical CDMO Product Portfolio
- 6.8.5 Lantheus Recent Developments
- 6.9 Medi-Radiopharma
- 6.9.1 Medi-Radiopharma Company Information
- 6.9.2 Medi-Radiopharma Business Overview
- 6.9.3 Medi-Radiopharma Radiopharmaceutical CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Medi-Radiopharma Radiopharmaceutical CDMO Product Portfolio
- 6.9.5 Medi-Radiopharma Recent Developments
- 6.10 Minerva Imaging
- 6.10.1 Minerva Imaging Company Information
- 6.10.2 Minerva Imaging Business Overview
- 6.10.3 Minerva Imaging Radiopharmaceutical CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Minerva Imaging Radiopharmaceutical CDMO Product Portfolio
- 6.10.5 Minerva Imaging Recent Developments
- 6.11 NorthStar
- 6.11.1 NorthStar Company Information
- 6.11.2 NorthStar Business Overview
- 6.11.3 NorthStar Radiopharmaceutical CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 NorthStar Radiopharmaceutical CDMO Product Portfolio
- 6.11.5 NorthStar Recent Developments
- 6.12 ROTOP Pharmaka GmbH
- 6.12.1 ROTOP Pharmaka GmbH Company Information
- 6.12.2 ROTOP Pharmaka GmbH Business Overview
- 6.12.3 ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 ROTOP Pharmaka GmbH Radiopharmaceutical CDMO Product Portfolio
- 6.12.5 ROTOP Pharmaka GmbH Recent Developments
- 6.13 Nucleus RadioPharma
- 6.13.1 Nucleus RadioPharma Company Information
- 6.13.2 Nucleus RadioPharma Business Overview
- 6.13.3 Nucleus RadioPharma Radiopharmaceutical CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Nucleus RadioPharma Radiopharmaceutical CDMO Product Portfolio
- 6.13.5 Nucleus RadioPharma Recent Developments
- 6.14 PharmaLogic
- 6.14.1 PharmaLogic Company Information
- 6.14.2 PharmaLogic Business Overview
- 6.14.3 PharmaLogic Radiopharmaceutical CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 PharmaLogic Radiopharmaceutical CDMO Product Portfolio
- 6.14.5 PharmaLogic Recent Developments
7 North America
- 7.1 North America Radiopharmaceutical CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Radiopharmaceutical CDMO Market Size by Country (2021-2026)
- 7.3 North America Radiopharmaceutical CDMO Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Radiopharmaceutical CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Radiopharmaceutical CDMO Market Size by Country (2021-2026)
- 8.3 Europe Radiopharmaceutical CDMO Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Radiopharmaceutical CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Radiopharmaceutical CDMO Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Radiopharmaceutical CDMO Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Radiopharmaceutical CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Radiopharmaceutical CDMO Market Size by Country (2021-2026)
- 10.3 South America Radiopharmaceutical CDMO Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Radiopharmaceutical CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Radiopharmaceutical CDMO Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Radiopharmaceutical CDMO Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst